Patents Assigned to CROWN BIOSCIENCE, INC. (TAICANG)
-
Patent number: 11640849Abstract: The present disclosure provides a diagnostic method based on pairwise comparison of cancers using transcriptome expression data. In one embodiment, the method comprises the steps of: obtaining a first gene expression profile of a first cancer sample having a first cancer type; obtaining a second gene expression profile of a second cancer sample having a second cancer type, wherein the second cancer type is different from the first cancer type; comparing said first gene expression profile with said second gene expression profile; and selecting N genes that are most differentially expressed in the first and the second gene expression profiles to generate pairwise differentially expressed genes (DEGs), wherein N is an integer between 10 and 100.Type: GrantFiled: September 9, 2016Date of Patent: May 2, 2023Assignee: CROWN BIOSCIENCE, INC. (TAICANG)Inventors: Sheng Guo, Henry Qixiang Li
-
Patent number: 11459618Abstract: A panel of gene expression markers for gastric cancer patient treated or to be treated by cetuximab is provided. Methods and compositions are also provided, e.g., kits, for evaluating gene expression levels of the markers and methods of using such gene expression levels to predict a gastric cancer patient's response to cetuximab.Type: GrantFiled: March 28, 2018Date of Patent: October 4, 2022Assignee: CROWN BIOSCIENCE, INC. (TAICANG)Inventors: Binchen Mao, Sheng Guo, Henry Qixiang Li
-
Patent number: 11339447Abstract: Provided in the disclosure relates to a panel of gene expression markers for cancer patient treated or to be treated by karenitecin. The disclosure provides methods and compositions, e.g., kits, for evaluating gene expression levels of the markers and methods of using such gene expression levels to predict a cancer patient's response to karenitecin. Such information can be used in determining prognosis and treatment options for cancer patients.Type: GrantFiled: March 28, 2018Date of Patent: May 24, 2022Assignee: CROWN BIOSCIENCE, INC. (TAICANG)Inventors: Binchen Mao, Dawei Chen, Sheng Guo, Henry Qixiang Li
-
Patent number: 11136625Abstract: Gene expression signature predictive of cancer patient response to multi-kinase inhibitor is disclosed. Also disclosed are methods predicting the efficacy of the multi-kinase inhibitor for treating cancer in a patient. Also disclosed are methods for distinguishing responders from non-responders to a multi-kinase inhibitor in treating cancer. Also disclosed are methods for treating a cancer patient with a multi-kinase inhibitor.Type: GrantFiled: August 28, 2014Date of Patent: October 5, 2021Assignee: CROWN BIOSCIENCE, INC. (TAICANG)Inventors: Sheng Guo, Daiwei Chen, Juan Zhang, Jie Cai, Henry Qixiang Li
-
Patent number: 11020494Abstract: The present disclosure provides non-human animal models of non-alcoholic fatty liver disease (NAFLD). Also provided are methods for producing the non-human animal models and uses of the non-human animal models to screen and evaluate agents for treating or preventing NAFLD.Type: GrantFiled: June 21, 2018Date of Patent: June 1, 2021Assignee: CROWN BIOSCIENCE INC. (TAICANG)Inventors: Richard Peterson, Charles Van Jackson, Gao Sun, Guodong Zhang, Yixin (Jim) Wang
-
Patent number: 10683550Abstract: The present disclosure provides methods of detecting a fusion gene of HNF4G and RSPO2 in a nucleic acid-containing sample, and a primer set, a probe set and a kit for detecting the fusion gene are also provided. Animal models for a human disease positive for the fusion gene are also provided herein. In addition, the present disclosure relates to the methods for assessing and identifying an agent effective on the fusion gene of HNF4G and RSPO2 or a human disease positive for a fusion gene of HNF4G and RSPO2 and thereby treating said disease are also provided.Type: GrantFiled: April 3, 2015Date of Patent: June 16, 2020Assignee: CROWN BIOSCIENCE, INC. (TAICANG)Inventors: Jie Cai, Henry Li
-
Patent number: 10501805Abstract: A method for predicting the responsiveness of a cancer cell to an MEK inhibitor, comprising detecting the presence of at least one mutation in one or more genes selected from the group consisting of ADAM12, COL14A1, TNN, and TP53, in the cancer cell, by contacting a nucleic acid sample derived from the cancer cell with at least one oligonucleotide which allows specific detection of the mutation; wherein presence of mutation in ADAM12, COL14A1, TNN, TP53 and/or any combination thereof is indicative of decreased responsiveness of the cancer cell to the ERK inhibitor.Type: GrantFiled: April 3, 2015Date of Patent: December 10, 2019Assignee: CROWN BIOSCIENCE, INC. (TAICANG)Inventors: Sheng Guo, Wubin Qian, Jinying Ning, Jing Zhang, Jixian Li, Zhu Mei
-
Patent number: 10442862Abstract: The present invention relates to methods for treating gastric neoplasias, in particular treating patients who have been previously determined to have an EGFR biomarker. Gastric carcinoma (GC) is one of the most common and deadest cancers with ?1 million diagnoses and ?0.7 million deaths each year worldwide, with high incidence in Eastern Asia.Type: GrantFiled: March 14, 2014Date of Patent: October 15, 2019Assignee: Crown Bioscience, Inc. (Taicang)Inventors: Jie Yang, Yiyou Chen, Henry Qixiang Li, Jie Cai
-
Publication number: 20180247014Abstract: The present disclosure provides a diagnostic method based on pairwise comparison of cancers using transcriptome expression data. In one embodiment, the method comprises the steps of: obtaining a first gene expression profile of a first cancer sample having a first cancer type; obtaining a second gene expression profile of a second cancer sample having a second cancer type, wherein the second cancer type is different from the first cancer type; comparing said first gene expression profile with said second gene expression profile; and selecting N genes that are most differentially expressed in the first and the second gene expression profiles to generate pairwise differentially expressed genes (DEGs), wherein N is an integer between 10 and 100.Type: ApplicationFiled: September 9, 2016Publication date: August 30, 2018Applicant: CROWN BIOSCIENCE, INC. (TAICANG)Inventors: Sheng GUO, Henry Qixiang LI
-
Patent number: 9921222Abstract: The present invention provides methods for the treatment of lung cancer patients, especially NSCLC with SCC or PLC using a drug against EGFR, such as an anti-EGFR antibody treatment, e.g., cetuximab. In addition, the present invention provides methods for identification or selection of lung cancer patients for the treatment with a drug against EGFR, such as an anti-EGFR antibody treatment, e.g., cetuximab based on histological determinations.Type: GrantFiled: July 31, 2013Date of Patent: March 20, 2018Assignee: CROWN BIOSCIENCE, INC. (TAICANG)Inventors: Henry Qixiang Li, Mengmeng Yang
-
Patent number: 9743646Abstract: The present invention provides an immuno-deficient animal useful as an animal model for a human disease associated with a first mutation of a target gene, wherein the animal comprises (a) a first human xenograft comprising the target gene comprising the first mutation; (b) a second human xenograft comprising the target gene but lacking the first mutation, wherein the first human xenograft and second human xenograft are isogenic. Also provided here are methods of producing the animal model and methods of using such animal model.Type: GrantFiled: April 6, 2015Date of Patent: August 29, 2017Assignee: CROWN BIOSCIENCE INC. (TAICANG)Inventors: Qian Shi, Yanmei Sun
-
Publication number: 20170114414Abstract: A method for predicting the responsiveness of a cancer cell to an MEK inhibitor, comprising detecting the presence of at least one mutation in one or more genes selected from the group consisting of ADAM12, COL14A1, TNN, and TP53, in the cancer cell, by contacting a nucleic acid sample derived from the cancer cell with at least one oligonucleotide which allows specific detection of the mutation; wherein presence of mutation in ADAM12, COL14A1, TNN, TP53 and/or any combination thereof is indicative of decreased responsiveness of the cancer cell to the ERK inhibitor.Type: ApplicationFiled: April 3, 2015Publication date: April 27, 2017Applicant: Crown Bioscience, Inc. (Taicang)Inventors: Sheng GUO, Wubin QIAN, Jinying NING, Jing ZHANG, Jixian LI, Zhu MEI
-
Publication number: 20160208328Abstract: Gene expression signature predictive of cancer patient response to multi-kinase inhibitor is disclosed. Also disclosed are methods predicting the efficacy of the multi-kinase inhibitor for treating cancer in a patient. Also disclosed are methods for distinguishing responders from non-responders to a multi-kinase inhibitor in treating cancer. Also disclosed are methods for treating a cancer patient with a multi-kinase inhibitor.Type: ApplicationFiled: August 28, 2014Publication date: July 21, 2016Applicant: Crown Bioscience, Inc. (Taicang)Inventors: Sheng GUO, Daiwei CHEN, Juan ZHANG, Jie CAI, Henry Qixiang LI
-
Publication number: 20160024216Abstract: The present invention relates to methods for treating gastric neoplasias, in particular treating patients who have been previously determined to have an EGFR biomarker. Gastric carcinoma (GC) is one of the most common and deadest cancers with ?1 million diagnoses and ?0.7 million deaths each year worldwide, with high incidence in Eastern Asia.Type: ApplicationFiled: March 14, 2014Publication date: January 28, 2016Applicant: CROWN BIOSCIENCE, INC. (TAICANG)Inventors: Jie YANG, Yiyou CHEN, Henry Qixiang LI, Jie CAI